[go: up one dir, main page]

CO6480954A2 - Método para producir una preparación altamente concentrada de inmunoglobulina de uso subcutaneo - Google Patents

Método para producir una preparación altamente concentrada de inmunoglobulina de uso subcutaneo

Info

Publication number
CO6480954A2
CO6480954A2 CO11179041A CO11179041A CO6480954A2 CO 6480954 A2 CO6480954 A2 CO 6480954A2 CO 11179041 A CO11179041 A CO 11179041A CO 11179041 A CO11179041 A CO 11179041A CO 6480954 A2 CO6480954 A2 CO 6480954A2
Authority
CO
Colombia
Prior art keywords
highly concentrated
producing
concentrated preparation
subcutaneous
subcutaneous immunoglobulin
Prior art date
Application number
CO11179041A
Other languages
English (en)
Inventor
Wolfgang Teschner
Harald Arno Butterweck
Azra Pljevljakovic
Theresa Friederike Bauer
Bernhard Koelbl
Hans-Peter Schwarz
Nebojsa Nikolic
Gerhard Poelsler
Johanna Kindermann
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6480954(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of CO6480954A2 publication Critical patent/CO6480954A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Método novedoso y mejorado para preparar una composición altamente concentrada de inmunoglobulina a partir de plasma combinado para una inyección subcutánea. Composición de uso subcutáneo que comprende 20% o más de inmunoglobulina.
CO11179041A 2009-05-27 2011-12-27 Método para producir una preparación altamente concentrada de inmunoglobulina de uso subcutaneo CO6480954A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18160609P 2009-05-27 2009-05-27

Publications (1)

Publication Number Publication Date
CO6480954A2 true CO6480954A2 (es) 2012-07-16

Family

ID=42335649

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11179041A CO6480954A2 (es) 2009-05-27 2011-12-27 Método para producir una preparación altamente concentrada de inmunoglobulina de uso subcutaneo

Country Status (18)

Country Link
US (5) US8546548B2 (es)
EP (3) EP3708581A3 (es)
JP (1) JP5341252B2 (es)
KR (1) KR101464032B1 (es)
CN (1) CN102459331B (es)
AR (1) AR076607A1 (es)
AU (6) AU2010253830B2 (es)
BR (1) BRPI1012082B1 (es)
CA (1) CA2763138A1 (es)
CL (2) CL2011002996A1 (es)
CO (1) CO6480954A2 (es)
EA (1) EA023382B1 (es)
HK (1) HK1200843A1 (es)
MX (1) MX2011012576A (es)
MY (1) MY157239A (es)
SG (1) SG176256A1 (es)
TW (1) TWI445714B (es)
WO (1) WO2010138736A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US8546548B2 (en) * 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
NO2462158T3 (es) 2009-08-06 2018-06-09
PT2477603E (pt) * 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
FR2962650B1 (fr) * 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
EA032336B1 (ru) 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
SG11201400233TA (en) * 2011-08-26 2014-08-28 Baxter Int Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
WO2013041677A1 (en) 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor
WO2013090636A1 (en) 2011-12-13 2013-06-20 Baxter International Inc. Measurement of autoantibodies at low conductivity conditions with increased sensitivity
CN102532307B (zh) * 2012-02-22 2013-06-12 成都蓉生药业有限责任公司 一种制备人免疫球蛋白的方法
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
US20150157619A1 (en) * 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
EP2964255B1 (en) 2013-03-08 2020-11-04 CSL Behring GmbH Treatment and prevention of remote ischemia-reperfusion injury
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
CA2930687C (en) * 2013-11-15 2024-04-23 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
US20160287634A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Method of manufacturing an afod intravenous injection from fraction iv to prevent and kill hiv-1 and hiv-2
US10532087B2 (en) 2015-06-03 2020-01-14 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
FR3081328B1 (fr) * 2018-05-24 2021-01-01 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CR20210521A (es) * 2019-04-18 2022-04-01 Janssen Biotech Inc Glicoproteínas saliladas
WO2023170553A1 (en) 2022-03-07 2023-09-14 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
CN117069836B (zh) * 2023-09-22 2024-08-27 武汉中生毓晋生物医药有限责任公司 一种抗人t细胞兔免疫球蛋白的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3929411A1 (de) 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
US4892826A (en) 1988-10-11 1990-01-09 Abbott Laboratories Process for the preparation of urokinase derivatives
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
AT405739B (de) 1997-09-19 1999-11-25 Immuno Ag Verfahren zur reinigung von antithrombin iii
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
DK2272870T3 (da) 1998-06-09 2013-08-05 Csl Behring Ag Fremgangsmåde til fremstilling af immunoglobuliner med henblik på intravenøs indgivelse og andre immunoglobulin-lignende produkter.
EP2272870B1 (en) * 1998-06-09 2013-05-08 CSL Behring AG Process for manufacturing immunoglobulins for intravenous administration and other immunoglobulin-like products
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP2005508338A (ja) 2001-10-04 2005-03-31 プロテイン セラピューティクス、インク． 免疫性疾患を処置するためのガンマグロブリンの使用
EP1664119A1 (en) 2003-09-08 2006-06-07 Medical Research Council Method for the treatment or prophylaxis of tuberculosis
BRPI0507298A (pt) 2004-01-30 2007-07-03 Suomen Punainen Risti Veripalv processo para a produção de imunoglobulina segura a vìrus
US7553938B2 (en) 2004-02-27 2009-06-30 Octapharma Ag Method of providing a purified, virus safe antibody preparation
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2009021708A2 (en) 2007-08-13 2009-02-19 Baxter International Inc. Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
CN101279246B (zh) * 2007-12-28 2011-07-27 华侨大学 一种嗜硫性磁性复合微球的制备方法和用此复合微球分离免疫球蛋白g的方法
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
US8546548B2 (en) * 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

Also Published As

Publication number Publication date
EP2762492A2 (en) 2014-08-06
MX2011012576A (es) 2012-05-08
AU2010253830A1 (en) 2011-12-15
CL2011002996A1 (es) 2012-10-19
AU2020204244A1 (en) 2020-07-16
WO2010138736A2 (en) 2010-12-02
US20100330071A1 (en) 2010-12-30
US11242380B2 (en) 2022-02-08
AU2022228125A1 (en) 2022-09-29
AU2022228125B2 (en) 2024-02-29
BRPI1012082A2 (pt) 2019-04-02
CN102459331B (zh) 2015-01-28
AU2018200548B2 (en) 2020-04-02
CA2763138A1 (en) 2010-12-02
AU2016203542A1 (en) 2016-06-16
CN102459331A (zh) 2012-05-16
EP2435474A2 (en) 2012-04-04
TWI445714B (zh) 2014-07-21
US20220153823A1 (en) 2022-05-19
SG176256A1 (en) 2012-01-30
EA201171481A1 (ru) 2012-07-30
US20140030252A1 (en) 2014-01-30
EP3708581A3 (en) 2021-10-20
EP3708581A1 (en) 2020-09-16
US10125189B2 (en) 2018-11-13
JP2012528190A (ja) 2012-11-12
US8546548B2 (en) 2013-10-01
CL2013001673A1 (es) 2013-12-06
AU2020204244B2 (en) 2022-08-18
KR20140014403A (ko) 2014-02-06
US9175068B2 (en) 2015-11-03
EA023382B1 (ru) 2016-05-31
US20160244512A1 (en) 2016-08-25
AU2010253830B2 (en) 2016-03-03
AU2016203542B2 (en) 2018-02-15
AU2018200548A1 (en) 2018-02-15
TW201107344A (en) 2011-03-01
KR101464032B1 (ko) 2014-11-27
JP5341252B2 (ja) 2013-11-13
MY157239A (en) 2016-05-13
WO2010138736A3 (en) 2011-03-17
AU2024203600A1 (en) 2024-06-20
HK1200843A1 (en) 2015-08-14
US20190085064A1 (en) 2019-03-21
BRPI1012082B1 (pt) 2022-08-16
AR076607A1 (es) 2011-06-22
EP2762492A3 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
CO6480954A2 (es) Método para producir una preparación altamente concentrada de inmunoglobulina de uso subcutaneo
BRPI0823506A8 (pt) composições e métodos para a produção de isoprene
UY32049A (es) Inhibidores de cmet
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
ES2571224T3 (es) Uso de compuestos de filamentos de celulosa y acetato de celulosa para mejorar la biodegradabilidad
BR112014016047A8 (pt) composição de compósito degradável, composição, e método de uso um compósito degradável
BR112015015528A8 (pt) composição e método para produzir um composto
MX2010002836A (es) Bortezomib y proceso para la produccion del mismo.
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
CL2011002451A1 (es) Composicion que comprende al menos un flavonoide util para preparar producto que suministran una incrementada biodisponibilidad de hesperetina. uso de dicha composicion.
CL2012000258A1 (es) Proceso para la preparacion de composicion de aglomerante hidraulico asperjable que contiene como principales componentes agua, agregados, aglomerante hidraulico, acelerador de fraguado, aglomerante hidraulico asperjable; composicion; y uso
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
MX2018008597A (es) Composiciones inyectables de melfalan que comprenden un derivado de ciclodextrina y metodos de fabricacion y uso de las mismas.
BRPI0911554A2 (pt) Microemulsão, processo para a preparação de uma microemulsão, e, uso da microemulsão.
BR112012011328A2 (pt) inibidores de akt
CL2013000734A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
BR112012010760A2 (pt) caldo de fermentação inseticida a partir de actinomicetos
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
IN2012DN03379A (es)
UA115221C2 (uk) Спосіб активації та кон'югації фактора коагуляції
MX2014004131A (es) Formulaciones compuestas y metodos para hacer y usar las mismas.
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання

Legal Events

Date Code Title Description
FC Application refused